TY - JOUR
T1 - Destabilization and fusion of zwitterionic large unilamellar lipid vesicles induced by a β-type structure of the HIV-1 fusion peptide
AU - Nieva, José Luis
AU - Nir, Shlomo
AU - Wilschut, Jan
PY - 1998
Y1 - 1998
N2 - The peptide HIVarg, corresponding to a sequence of 23 amino acid residues at the N-terminus of HIV-1 gp41, has the capacity to induce fusion of large unilamellar vesicles (LUV) consisting of negatively charged or zwitterionic phospholipids. In the present study, we further characterize this destabiliration and fusion process using LUV consisting of phosphatidylcholine, phosphatidylethanolamine and cholesterol (molar ratio, 1: 1: 1). Evidence for fusion includes a demonstration of membrane lipid mixing as well as mixing of aqueous vesicle contents. Kinetic analysis of the overall process of vesicle aggregation and fusion revealed that the rate constant of the fusion step per se increased dramatically with the peptide- to-lipid molar ratio, indicating that the peptide acts as a true fusogen. The peptide caused the release of small molecules (ANTS/DPX), whereas large solutes (FITC-dextran, MW(av) 19,600) were partly retained. The estimated critical number of peptides per vesicle necessary to release vesicle contents, M = 2-4, indicates that leakage does not involve the formation of classical pores. Infrared spectroscopy of the peptide in the presence of liposomes demonstrated that the equilibrium conformation of the membrane- bound peptide is an antiparallel β-structure. This finding supports the notion that the HIV fusion peptide in a β-conformation has the capacity to perturb vesicle bilayers, inducing initial permeabilization and subsequent membrane fusion.
AB - The peptide HIVarg, corresponding to a sequence of 23 amino acid residues at the N-terminus of HIV-1 gp41, has the capacity to induce fusion of large unilamellar vesicles (LUV) consisting of negatively charged or zwitterionic phospholipids. In the present study, we further characterize this destabiliration and fusion process using LUV consisting of phosphatidylcholine, phosphatidylethanolamine and cholesterol (molar ratio, 1: 1: 1). Evidence for fusion includes a demonstration of membrane lipid mixing as well as mixing of aqueous vesicle contents. Kinetic analysis of the overall process of vesicle aggregation and fusion revealed that the rate constant of the fusion step per se increased dramatically with the peptide- to-lipid molar ratio, indicating that the peptide acts as a true fusogen. The peptide caused the release of small molecules (ANTS/DPX), whereas large solutes (FITC-dextran, MW(av) 19,600) were partly retained. The estimated critical number of peptides per vesicle necessary to release vesicle contents, M = 2-4, indicates that leakage does not involve the formation of classical pores. Infrared spectroscopy of the peptide in the presence of liposomes demonstrated that the equilibrium conformation of the membrane- bound peptide is an antiparallel β-structure. This finding supports the notion that the HIV fusion peptide in a β-conformation has the capacity to perturb vesicle bilayers, inducing initial permeabilization and subsequent membrane fusion.
KW - Fusion peptide
KW - HIV-1
KW - Lipidpeptide interaction
KW - Liposome
KW - Membrane fusion
UR - http://www.scopus.com/inward/record.url?scp=0031861456&partnerID=8YFLogxK
U2 - 10.3109/08982109809035524
DO - 10.3109/08982109809035524
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0031861456
SN - 0898-2104
VL - 8
SP - 165
EP - 182
JO - Journal of Liposome Research
JF - Journal of Liposome Research
IS - 2
ER -